CD274 and urothelial carcinoma: Additionally, a cohort of urothelial carcinoma patients treated with PDL-1 inhibitor atezolizumab was studied for validation, and it revealed that patients with higher lactate scores have poorer prognoses than the ones with lower lactate scores (P = 0.026) (Figure 6D).